A clinical trial on NSCLC patients who received treatment with immunotherapy revealed that patients who had no durable benefit had the highest copy number–altered genome fragments, but the variants in EGFR and STK11 related to benefit were lacking.36 Here, STK11 is linked to non-small cell lung carcinoma.